Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance.
Blog Post
Scientific breakthroughs accelerate HIV prevention—but only when they are matched with bold advocacy, sustained investment and equitable access. This month’s roundup highlights key prevention news, developments and takeaways from AVAC and explores what’s needed and what’s next to ensure the latest innovations move beyond headlines and into the hands of the communities that need them most.
Blog Post
At AIDS 2026 in Rio de Janeiro, there were difficult conversations around tensions playing out over the future of the AIDS response and the role of USG; big science across HIV prevention, treatment and cure; and strong advocacy calling for greater access, scale and speed for available products. AVAC’s Grace Kumwenda reflects on the conversations and news out of Rio, including big questions that will continue to inform AVAC’s work: What does this actually mean for people and the People’s Research Agenda? What does it mean for the field and the future?
Blog Post
AVAC is pleased to announce the 2026 Alumni Fellows from the HIV Cure Academy Program. This year, five alumni are putting what they gained through the Academies into action—strengthening community engagement, informing policy and advancing HIV cure research in diverse settings across Africa and the US. These grants build on a growing network of Cure Academy alumni who are translating what they learn into meaningful advocacy and action in their communities. Read on to learn more about the 2026 Cure Fellows and their projects and check back throughout the year for updates on their work to advance HIV cure research.
showing 1-10 of 1257
Scientific breakthroughs accelerate HIV prevention—but only when they are matched with bold advocacy, sustained investment and equitable access. This month’s roundup highlights key prevention news, developments and takeaways from AVAC and explores what’s needed and what’s next to ensure the latest innovations move beyond headlines and into the hands of the communities that need them most.
Prevention Option:
At AIDS 2026 in Rio de Janeiro, there were difficult conversations around tensions playing out over the future of the AIDS response and the role of USG; big science across HIV prevention, treatment and cure; and strong advocacy calling for greater access, scale and speed for available products. AVAC’s Grace Kumwenda reflects on the conversations and news out of Rio, including big questions that will continue to inform AVAC’s work: What does this actually mean for people and the People’s Research Agenda? What does it mean for the field and the future?
Prevention Option:
AVAC is pleased to announce the 2026 Alumni Fellows from the HIV Cure Academy Program. This year, five alumni are putting what they gained through the Academies into action—strengthening community engagement, informing policy and advancing HIV cure research in diverse settings across Africa and the US. These grants build on a growing network of Cure Academy alumni who are translating what they learn into meaningful advocacy and action in their communities. Read on to learn more about the 2026 Cure Fellows and their projects and check back throughout the year for updates on their work to advance HIV cure research.
Prevention Option:
Topic:
This week, the US Administration announced $2 billion in global health funding for faith-based organizations; US Congress intensified oversight of PEPFAR and the bilateral global health agreements; the NIH moves to restrict policy-focused research; and – perhaps most alarmingly – the US President issued an executive order rewriting longstanding, evidence-based childhood vaccine recommendations.
Prevention Option:
This week, the US Senate Committee on Homeland Security & Governmental Affairs voted along party lines to hold Anthony Fauci in contempt of Congress for his refusal to answer questions during last week’s hearing on the COVID-19 response testimony – while it was rumored that Steven Quay, a lab-leak proponent, is in line for Fauci’s old job. At the same time, the US Senate Appropriations Committee did step up to stop the White House OMB’s politicization of federal research grants. There’s also – finally – a new leader of the US Centers for Disease Control and Prevention (CDC). And the HIV/AIDS community is unpacking major themes emerging from the AIDS 2026 conference.
Prevention Option:
AVAC vehemently opposes the decision by the U.S. Senate Homeland Security and Governmental Affairs Committee to hold Dr. Anthony Fauci in contempt for his refusal to answer questions during last week’s hearing on the COVID-19 response. Certain members of the committee have made clear their intentions to pin the shortcomings of the U.S. response to COVID-19 on others by blaming and dragging renowned government scientists and public health practitioners such as Dr. Fauci through politicized proceedings without any evidence and using conspiratorial conjecture.
Following the AIDS 2026 conference in Rio de Janeiro, our team compiled a list of AVAC’s top 10 takeaways. These topics sparked discussions and ideas among our team and AVAC’s larger partner network, and will carry our work well into the future.
Prevention Option:
Following AIDS 2026 in Rio de Janeiro, AVAC’s Executive Director Mitchell Warren reflects on a week of conversations, sessions, and new data. As he puts it, Rio was a reminder that science has never been stronger, communities have never been more ready, and the need has never been more urgent. Ending HIV is no longer limited by what we know, it is limited only by the courage to act.
Prevention Option:
Scientists and advocates gathered in Rio for the 26th International AIDS Conference (AIDS 2026) this week to discuss the future of the HIV response, just as former NIAID Director Anthony Fauci appeared before a hostile Senate Committee on Homeland Security & Governmental Affairs, reminding us that the greatest barriers to ending HIV are increasingly political, not scientific. In addition, this week’s issue covers the US Administration’s use of vaccine funding as leverage in negotiations with Gavi and a new policy restricting gain-of-function research.
As the AIDS 2026 conference enters its second half, one message has emerged above all others: the barriers to ending HIV are no longer primarily scientific; they are political. Read on for AVAC’s highlights so far at the conference.
showing 1-10 of 1257
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.
A comprehensive round-up of HIV prevention media coverage and scientific publications.
Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.
A collection of official statements from AVAC.
Media clippings featuring AVAC, its staff and close partners in the news media.